ClinicalTrials.gg
Active, not recruitingNCT07215624STOP-VTEUpdated Nov 10, 2026

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

An observational study in Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm and Malignant Genitourinary System Neoplasm, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 104 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Wake Forest University Health Sciences · Observational

How we know

Updated Nov 10, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
22nd of 64
500 · median 172
Started
2026
with 14 others
Observational
64 of 316
20 open now
Primary completion
2027-03
later than 41 of 113 live
Registered
297th of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 22nd largest by planned enrollment of the 64 observational ones that give a count, is one of 15 that started in 2026, is one of 64 observational ones, reaches primary completion later than 41 of the 113 other live ones, and was the 297th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate self-reported utilization of guideline concordant extended venous thromboembolism (VTE) prophylaxis (ePPx) following abdominopelvic cancer surgery within a sample of surgeons practicing within NCORP based on the Part 1 surgeon survey.

SECONDARY OBJECTIVES:

I. Evaluate site factors (e.g., proportion of publicly insured patients, proportion of Black patients, presence of a medical school, NCI designation) and surgeon factors (e.g., fellowship training, years in practice) associated with surgeon self-reported guideline concordant ePPx utilization (Part 1).

II. Conduct semi-structured interviews among a subset of surgeons and surgical APPs to assess: 1) Barriers/facilitators toward ePPx after cancer surgery and 2) Acceptability of clinical decision support tools to support VTE prophylaxis prescribing (Part 2).

III. Extract EHR data from select practices to assess the feasibility of query-based electronic health record (EHR) data extraction for identification of (i) patients undergoing cancer surgery, and (ii) prescription of guideline concordant ePPx among eligible patients (Part 3).

OUTLINE: This is an observational study.

PART 1: Surgeons and APPs complete a survey on study. After completion of surgeon or APP survey, site contact person or Cancer Care Delivery Research (CCDR) lead complete site surveys on study.

PART 2: A subset of surgeons and APPs from part 1 complete a semi-structured interview on study.

PART 3: Site contact person or CCDR lead complete a survey to identify a EHR Report Specialist on study. EHR Report Specialist performs an EHR Data Extraction and provides feedback on the process in a survey.

03

Conditions studied

  • Malignant Digestive System Neoplasm
  • Malignant Female Reproductive System Neoplasm
  • Malignant Genitourinary System Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This multi-part study employs a mixed-methods design to evaluate the utilization of ePPx following abdominopelvic cancer surgery within the NCORP network. Part 1 involves a cross-sectional survey of at least 100 surgeons/APPs from at least 25 NCORP sites to evaluate practice patterns related to ePPx. Part 2 utilizes purposive sampling to conduct interviews with 11-25 surgeons/APPs from Part 1 to obtain granular detail about barriers and facilitators to guideline concordant utilization of ePPx. Part 3 will purposively sample 6 practices identified in Part 1 to evaluate the feasibility of EHR queries to assess ePPx utilization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:

* Any surgeon performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgeons do not need to be involved in research or have a Cancer Therapy Evaluation Program Identification (CTEP ID) to participate in this study

SURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:

* APPs providing postoperative care to patients operated by surgeons performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgical APPs do not need to be involved in research or have a CTEP ID to participate in this study

SURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:

* Must have completed the STOP-VTE Survey - Surgeon electronically (preferred) or on paper and have it transferred to Research Electronic Data Capture (REDCap) by the contact person(s)

SURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:

* Must have completed the STOP-VTE Survey - APP electronically (preferred) or on paper and have it transferred to REDCap by the contact person(s)

SITE ELIGIBILITY PART 1-SITE ENROLLMENT IN OPEN:

* Have at least one eligible surgeon or surgical APP who completed the STOP-VTE Survey - Surgeon/APP

Exclusion criteria

Exclusion Criteria:

  • N/A
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational Part 1

    Surgeons and APPs complete a survey on study. After completion of surgeon or APP survey, site contact person or CCDR lead complete site surveys on study.

    Other: Non-Interventional Study

  • Observational Part 2

    Subset of surgeons and APPs from Part 1 complete a semi-structured interview on study.

    Other: Non-Interventional Study

  • Observational Part 3

    Site contact person or CCDR lead complete a survey to identify a EHR Report Specialist on study. EHR Report Specialist performs an EHR Data Extraction and provides feedback on the process in a survey.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Self-reported utilization of guideline concordant ePPx for surgeons (Part 1)

    Will apply only to surgeons completing the Part 1 survey. Will be defined as answering "Yes, all cases or almost all cases" on the survey question asking about prescription of ePPx after discharge. The proportion of surgeons self-reporting utilization of guideline concordant ePPx will be estimated and reported along with an exact 95% confidence interval.

    Time frame: After 1 year from start of Part 1

Secondary outcomes

  1. Self-reported utilization of guideline concordant ePPx for surgeons within strata defined by site and surgeon factors (Part 1)

    Self reported utilization as defined above for the primary outcome measure will be reported within strata defined by: * Site factors (e.g., proportion of publicly insured patients, proportion of Black patients, presence of a medical school, NCI designation) * Surgeon factors (e.g., fellowship training, years in practice)

    Time frame: After 1 year from start of Part 1

  2. Barriers and facilitators toward ePPx after cancer surgery, and acceptability of clinical decision support tools to support VTE prophylaxis prescribing (Part 2)

    Themes from qualitative interviews by surgeons and APPs

    Time frame: After 6 months from start of Part 2

  3. Feasibility (i.e., proportion of practices able to provide data) of EHR queries from selected practices to inform future trial (Part 3)

    Considered feasible if at least 4 of the 6 practices who agreed to participate are able to provide data on both patients undergoing cancer surgery and prescription of guideline concordant ePPx among eligible patients

    Time frame: After 6 months from start of Part 3

07

Study locations

104 sites

Showing the first 100 of 104 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Time frame: 6 months after publication for a 2 year duration

Access criteria: upon request to NCORP@wakehealth.edu

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's planned 13 months is below that.

Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 10, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Mar 1, 2027was Dec 2026
CompletionEst.
Jun 1, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
45 sites added
Show 45 added (45 United States)
  • Kingman Regional Medical Center · Kingman, United States
  • Kaiser Permanente-Oakland · Oakland, United States
  • Kaiser Permanente-San Francisco · San Francisco, United States
  • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
  • Kaiser Permanente-Walnut Creek · Walnut Creek, United States
  • Holy Cross Hospital · Fort Lauderdale, United States
  • University of Hawaii Cancer Center · Honolulu, United States
  • Tripler Army Medical Center · Honolulu, United States
  • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
  • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
  • OSF Saint Anthony's Health Center · Alton, United States
  • John H Stroger Jr Hospital of Cook County · Chicago, United States
  • University of Kansas Cancer Center · Kansas City, United States
  • University of Kansas Hospital-Indian Creek Campus · Overland Park, United States
  • University of Kansas Hospital-Westwood Cancer Center · Westwood, United States
  • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Grand Rapids, United States
  • University of Michigan Health - Sparrow Lansing · Lansing, United States
  • Essentia Health Saint Mary's - Detroit Lakes Clinic · Detroit Lakes, United States
  • Essentia Health Cancer Center · Duluth, United States
  • Essentia Health Virginia Clinic · Virginia, United States
  • Billings Clinic Cancer Center · Billings, United States
  • Bozeman Health Deaconess Hospital · Bozeman, United States
  • University of New Mexico Cancer Center · Albuquerque, United States
  • Montefiore Medical Center-Einstein Campus · The Bronx, United States
  • Sanford Bismarck Medical Center · Bismarck, United States
  • Essentia Health Cancer Center-South University Clinic · Fargo, United States
  • Sanford Roger Maris Cancer Center · Fargo, United States
  • Licking Memorial Hospital · Newark, United States
  • Providence Portland Medical Center · Portland, United States
  • …and 15 more on the registry record
across 2 updates, Oct 7, 2026 – Nov 4, 2026
Primary completion
Dec 1, 2026→Mar 1, 2027
Nov 10, 2026
Show all 3 updates
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 1, 2026→Mar 1, 2027
    + 2 other changes: contact details and site details
  2. Nov 4, 2026
    1 site added
    Show site
    • Montefiore Medical Center - Moses Campus · The Bronx, United States
    + 1 other change: verification date
  3. Oct 7, 2026
    44 sites added
    Show 44 added (44 United States)
    • Kingman Regional Medical Center · Kingman, United States
    • Kaiser Permanente-Oakland · Oakland, United States
    • Kaiser Permanente-San Francisco · San Francisco, United States
    • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
    • Kaiser Permanente-Walnut Creek · Walnut Creek, United States
    • Holy Cross Hospital · Fort Lauderdale, United States
    • University of Hawaii Cancer Center · Honolulu, United States
    • Tripler Army Medical Center · Honolulu, United States
    • Saint Alphonsus Cancer Care Center-Boise · Boise, United States
    • Kootenai Health - Coeur d'Alene · Coeur d'Alene, United States
    • OSF Saint Anthony's Health Center · Alton, United States
    • John H Stroger Jr Hospital of Cook County · Chicago, United States
    • University of Kansas Cancer Center · Kansas City, United States
    • University of Kansas Hospital-Indian Creek Campus · Overland Park, United States
    • University of Kansas Hospital-Westwood Cancer Center · Westwood, United States
    • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
    • Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Grand Rapids, United States
    • University of Michigan Health - Sparrow Lansing · Lansing, United States
    • Essentia Health Saint Mary's - Detroit Lakes Clinic · Detroit Lakes, United States
    • Essentia Health Cancer Center · Duluth, United States
    • Essentia Health Virginia Clinic · Virginia, United States
    • Billings Clinic Cancer Center · Billings, United States
    • Bozeman Health Deaconess Hospital · Bozeman, United States
    • University of New Mexico Cancer Center · Albuquerque, United States
    • Montefiore Medical Center-Einstein Campus · The Bronx, United States
    • Sanford Bismarck Medical Center · Bismarck, United States
    • Essentia Health Cancer Center-South University Clinic · Fargo, United States
    • Sanford Roger Maris Cancer Center · Fargo, United States
    • Licking Memorial Hospital · Newark, United States
    • Providence Portland Medical Center · Portland, United States
    • …and 14 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07215624
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Jan 15, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Glenn Lesser, MD
study chair · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion